Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jules L Dienstag

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Hepatology (Baltimore, Md.)|March 24, 2021
Introducing Raymond T. Chung, M.D., Our 2021 AASLD PresidentJules L Dienstag
Perspectives in Biology and Medicine|March 15, 2011
Evolution of the New Pathway curriculum at Harvard Medical School: the new integrated curriculumJules L Dienstag
Annals of Internal Medicine|May 17, 2006
Hepatitis C: a bitter harvestJules L Dienstag
The New England Journal of Medicine|October 4, 2008
Hepatitis B virus infectionJules L Dienstag
Journal of Hepatology|January 25, 2005
The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis BJules L Dienstag
The American Journal of Gastroenterology|August 6, 2010
Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eyeJules L Dienstag
The New England Journal of Medicine|July 20, 2012
The case for the new MCATJules L Dienstag
The Journal of Infectious Diseases|April 22, 2008
Hepatitis A: the vaccine dividendJules L Dienstag
Hepatology (Baltimore, Md.)|April 29, 2009
Benefits and risks of nucleoside analog therapy for hepatitis BJules L Dienstag
The American Journal of Gastroenterology|February 2, 2006
Looking to the future: new agents for chronic hepatitis BJules L Dienstag
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Hepatology (Baltimore, Md.)|March 24, 2021
Introducing Raymond T. Chung, M.D., Our 2021 AASLD PresidentJules L Dienstag
Perspectives in Biology and Medicine|March 15, 2011
Evolution of the New Pathway curriculum at Harvard Medical School: the new integrated curriculumJules L Dienstag
Annals of Internal Medicine|May 17, 2006
Hepatitis C: a bitter harvestJules L Dienstag
The New England Journal of Medicine|October 4, 2008
Hepatitis B virus infectionJules L Dienstag
Journal of Hepatology|January 25, 2005
The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis BJules L Dienstag
The American Journal of Gastroenterology|August 6, 2010
Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eyeJules L Dienstag
The New England Journal of Medicine|July 20, 2012
The case for the new MCATJules L Dienstag
The Journal of Infectious Diseases|April 22, 2008
Hepatitis A: the vaccine dividendJules L Dienstag
Hepatology (Baltimore, Md.)|April 29, 2009
Benefits and risks of nucleoside analog therapy for hepatitis BJules L Dienstag
The American Journal of Gastroenterology|February 2, 2006
Looking to the future: new agents for chronic hepatitis BJules L Dienstag
Pageof 9